Cytarabine/gemtuzumab-ozogamicin: Hyperbilirubinaemia: case report.

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study conducted between 2007 and 2019 involving 18 patients, a patient [age and sex not stated] was described who developed hyperbilirubinaemia during treatment with cytarabine and gemtuzumab ozogamicin for acute myeloid leukaemia [ I not dosages stated; routes and outcome not stated i ]. The patient had relapse of acute myeloid leukaemia after an allogeneic hematopoietic cell transplant. Gemtuzumab ozogamicin combined with intensive chemotherapy in acute myeloid leukemia patients relapsing after allogenic stem-cell transplantation. [Extracted from the article]